Brain Cancer

New clinical trials are advancing in hard-to-treat cancers, offering targeted and less toxic options for patients with limited treatment paths.

The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.

Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized after initial progression.

Kasey Rangan discusses ways that families of patients with pediatric brain cancer can advocate for themselves, especially when it comes to mental health.

After a brain tumor diagnosis and infection, I celebrate recovery with family at the beach, embracing life’s precious moments together.

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.

The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.

The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.

IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.

Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a study found.

Dr. Ranjit S. Bindra discusses recent advancements for the treatment of patients with primary brain tumors during Brain Cancer Awareness Month.

The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.

Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer.

An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy, outperforming single-image methods.

Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.

The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse intrinsic pontine glioma.

People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate.

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type of brain cancer.

The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a form of brain cancer.

A new comprehensive hereditary cancer solution offers genetic counseling and multigene panels to enhance early detection of disease's like brain cancer.

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with recurrent glioblastoma.